CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

por Buchbinder, Elizabeth I., Desai, Anupam
Publicado 2016

Cancer Therapy Targeting CD47/SIRPα

por Dizman, Nazli, Buchbinder, Elizabeth I.
Publicado 2021

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial...

por Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I.
Publicado 2015

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma

por Yeh, Jennifer E., Wan, Marilyn T., Alloo, Allireza, Ibrahim, Nageatte, Ott, Patrick A., Buchbinder, Elizabeth I., Lin, Jennifer Y.
Publicado 2022

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

por Naik, Girish S., Waikar, Sushrut S., Johnson, Alistair E. W., Buchbinder, Elizabeth I., Haq, Rizwan, Hodi, F. Stephen, Schoenfeld, Jonathan D., Ott, Patrick A.
Publicado 2019

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy

por Buchbinder, Elizabeth I., Pfaff, Kathleen L., Turner, Madison M., Manos, Michael, Ouyang, Olivia, Ott, Patrick A., Giobbie-Hurder, Anita, Rodig, Scott J., Hodi, F. Stephen
Publicado 2023

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma

por Ibrahim, Nageatte, Buchbinder, Elizabeth I., Granter, Scott R., Rodig, Scott J., Giobbie‐Hurder, Anita, Becerra, Carla, Tsiaras, Argyro, Gjini, Evisa, Fisher, David E., Hodi, F. Stephen
Publicado 2016

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

por Miller, Peter G., Sperling, Adam S., Gibson, Christopher J., Pozdnyakova, Olga, Wong, Waihay J., Manos, Michael P., Buchbinder, Elizabeth I., Hodi, F. Stephen, Ebert, Benjamin L., Davids, Matthew S.
Publicado 2020

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)

por Sun, James, Gastman, Brian R, McCahon, Lucy, Buchbinder, Elizabeth I, Puzanov, Igor, Nanni, Michele, Lewis, James M, Carvajal, Richard D, Singh-Kandah, Shahnaz, Desai, Anupam M, Raskin, Leon, Nielson, Carrie M, Ismail, Rubina, Zager, Jonathan S
Publicado 2020

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

por Buchbinder, Elizabeth I., Weirather, Jason L., Manos, Michael, Quattrochi, Brian J., Sholl, Lynette M., Brennick, Ryan C., Bowling, Peter, Bailey, Nancy, Magarace, Lisa, Ott, Patrick A., Haq, Rizwan, Izar, Benjamin, Giobbie‐Hurder, Anita, Hodi, F. Stephen
Publicado 2021

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

por Ott, Patrick A, Nazzaro, Matthew, Pfaff, Kathleen L, Gjini, Evisa, Felt, Kristen D, Wolff, Jacquelyn O, Buchbinder, Elizabeth I, Haq, Rizwan, Sullivan, Ryan J, Lawrence, Donald P, McDermott, David F, Severgnini, Mariano, Giobbie-Hurder, Anita, Rodig, Scott J, Stephen Hodi, F
Publicado 2021

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

por Buchbinder, Elizabeth I., Dutcher, Janice P., Daniels, Gregory A., Curti, Brendan D., Patel, Sapna P., Holtan, Shernan G., Miletello, Gerald P., Fishman, Mayer N., Gonzalez, Rene, Clark, Joseph I., Richart, John M., Lao, Christopher D., Tykodi, Scott S., Silk, Ann W., McDermott, David F.
Publicado 2019

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

por Buchbinder, Elizabeth I., Gunturi, Anasuya, Perritt, Jessica, Dutcher, Janice, Aung, Sandra, Kaufman, Howard L., Ernstoff, Marc S., Miletello, Girald P., Curti, Brendan D., Daniels, Gregory A., Patel, Sapna P., Kirkwood, John M., Hallmeyer, Sigrun, Clark, Joseph I., Gonzalez, Rene, Richart, John M., Lutzky, Joe, Morse, Michael A., Sullivan, Ryan J., McDermott, David F.
Publicado 2016

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

por Pavlick, Anna C, Ariyan, Charlotte E, Buchbinder, Elizabeth I, Davar, Diwakar, Gibney, Geoffrey T, Hamid, Omid, Hieken, Tina J, Izar, Benjamin, Johnson, Douglas B, Kulkarni, Rajan P, Luke, Jason J, Mitchell, Tara C, Mooradian, Meghan J, Rubin, Krista M, Salama, April KS, Shirai, Keisuke, Taube, Janis M, Tawbi, Hussein A, Tolley, J Keith, Valdueza, Caressa, Weiss, Sarah A, Wong, Michael K, Sullivan, Ryan J
Publicado 2023

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

por Li, Xuanyi, Sigworth, Elizabeth A., Wu, Adrianne H., Behrens, Jess, Etemad, Shervin A., Nagpal, Seema, Go, Ronald S., Wuichet, Kristin, Chen, Eddy J., Rubinstein, Samuel M., Venepalli, Neeta K., Tillman, Benjamin F., Cowan, Andrew J., Schoen, Martin W., Malty, Andrew, Greer, John P., Fernandes, Hermina D., Seifter, Ari, Chen, Qingxia, Chowdhery, Rozina A., Mohan, Sanjay R., Dewdney, Summer B., Osterman, Travis, Ambinder, Edward P., Buchbinder, Elizabeth I., Schwartz, Candice, Abraham, Ivy, Rioth, Matthew J., Singh, Naina, Sharma, Sanjai, Gibson, Michael K., Yang, Peter C., Warner, Jeremy L.
Publicado 2020